ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Interactive Brokers

Interactive Brokers
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P 500
5,562.00
-0.04%
US Tech 100
19,273.20
-0.16%
Dow Jones
40,401.16
-0.04%
Brent Oil
80.63
-1.09%
Bitcoin
65,642.41
-2.90%
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. Europe
  5. EU

  6. GeNeuro SA (GNRO) Quote

GeNeuro SA

GeNeuro SA (GNRO)

EU
0.0696
-0.0174
(-20.00%)
Closed July 23 11:30AM
Delayed by 15 minutes

Empower your portfolio: Real-time discussions and actionable trading ideas.

Premium

Key stats and details

Current Price
0.0696
Bid
0.068
Ask
0.077
Volume
172,691
0.068 Day's Range 0.09
0.068 52 Week Range 2.35
Market Cap
2.071M
Previous Close
0.087
Open
0.081
Last Trade
1500
@
0.0696
Last Trade Time
Financial Volume
-
VWAP
-
Average Volume (3m)
101,904
Shares Outstanding
29,760,933
Dividend Yield
-
PE Ratio
-
Earnings Per Share (EPS)
-
Revenue
-
Net Profit
-

About GeNeuro SA

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Website
www.geneuro.com
Headquarters
Geneva, Che
Founded
1970
GeNeuro SA is listed in the Pharmaceutical Preparations sector of the Euronext with ticker GNRO. The last closing price for GeNeuro was 0.09 €. Over the last year, GeNeuro shares have traded in a share price range of 0.068 € to 2.35 €.

GeNeuro currently has 29,760,933 shares outstanding. The market capitalization of GeNeuro is 2.59 € million.

GNRO Latest News

More News

GeNeuro Announces That It Submits a Request for a Debt Moratorium to the Geneva Court of First Instance

Regulatory News: GeNeuro (Euronext Paris : CH0308403085 - GNRO), a biopharmaceutical company developing new treatments for neurodegenerative and autoimmune diseases such as multiple sclerosis...

July 15 2024
Business Wire

GeNeuro : Fin du contrat de liquidité conclu avec GILBERT DUPONT

Regulatory News: La société GENEURO (Paris:GNRO) et la société GILBERT DUPONT ont mis fin au contrat de liquidité conclu le 06 mars 2021. Cette résiliation a pris effet le 30 juin 2024 au soir. A...

July 10 2024
Business Wire

Geneuro SA: Half-Yearly Report on the Liquidity Contract with Gilbert Dupont

Market: Euronext Paris ISIN code / Mnemo: CH0308403085 / GNRO Web site: www.geneuro.com Regulatory News: Pursuant to the liquidity contract entrusted by GENEURO SA (Paris:GNRO) to Gilbert Dupont...

July 03 2024
Business Wire

GeNeuro annonce les résultats de l’essai GNC-501 dans le syndrome post-Covid-19

Regulatory News: GeNeuro (Euronext Paris: CH0308403085 – GNRO): L'essai clinique GNC-501 est une étude de phase 2 chez des patients souffrant de syndromes neuropsychiatriques post-COVID-19...

June 28 2024
Business Wire

GeNeuro Announces Approval of all Resolutions Proposed at 2024 Annual General Meeting

81.54% of the Company’s share capital was represented at the AGM and resolutions were all unanimously approved Regulatory News: GeNeuro (Euronext Paris: CH0308403085 - GNRO), a biopharmaceutical...

June 14 2024
Business Wire

Availability of documents and information for the annual shareholders’ meeting of June 12, 2024

Regulatory News: GeNeuro (Euronext Paris : CH0308403085 - GNRO), a biopharmaceutical company focused on halting the progression of neurodegenerative and autoimmune diseases such as multiple...

May 29 2024
Business Wire

GeNeuro annonce la dernière visite du dernier patient dans son étude post-COVID et confirme que les principaux résultats seront disponibles à fin juin 2024

L'étude GNC-501 contre le post-Covid a réalisé la dernière visite de patient permettant de finaliser l’étude. L'objectif de l'étude est d'évaluer l'efficacité et l'innocuité du temelimab sur...

May 16 2024
Business Wire

GeNeuro Publishes its 2024 Universal Registration Document

Regulatory News: GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company developing novel treatments for neurodegenerative and autoimmune diseases such as multiple sclerosis...

May 02 2024
Business Wire
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.0114-14.07407407410.0810.11850.0681088320.08669134DE
4-1.7704-96.21739130431.841.990.0682567670.16225499DE
12-1.3954-95.24914675771.4652.350.0681019040.34084324DE
26-1.1904-94.47619047621.262.350.068520100.4000222DE
52-1.5104-95.59493670891.582.350.068298500.51659587DE
156-3.4104-983.484.390.068132521.09898424DE
260-2.9304-97.6836.280.068104601.75212116DE

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
DCAPUnity Wealth Partners Dynamic Capital Appreciation & Options ETF
 20.10
(839.25%)
128.77k
RGCRegencell Bioscience Holdings Ltd
$ 19.5999
(481.60%)
1.07M
SLRXSalarius Pharmaceuticals Inc
$ 2.575
(67.21%)
59.13M
ATPCAgape ATP Corporation
$ 0.2053
(43.57%)
104.76M
QXOQXO Inc
$ 81.9899
(36.42%)
67.05k
FLYEFly E Group Inc
$ 1.07
(-83.23%)
22.02M
RNAZTransCode Therapeutics Inc
$ 0.2996
(-62.20%)
8.9M
JAGXJaguar Health Inc
$ 1.715
(-59.84%)
14.59M
MIRAMIRA Pharmaceuticals Inc
$ 2.6799
(-46.51%)
24.7M
IVPInspire Veterinary Partners Inc
$ 5.30
(-42.64%)
1.34M
SPWRSunPower Corporation
$ 0.93673
(30.86%)
177.03M
ADILAdial Pharmaceuticals Inc
$ 1.435
(35.38%)
157.99M
SLNASelina Hospitality PLC
$ 0.0257
(-30.54%)
150.16M
NVDANVIDIA Corporation
$ 122.841
(-0.57%)
138.99M
SQQQProShares UltraPro Short QQQ
$ 8.1099
(0.25%)
109.79M

Discussion

View Full Feed
QuantumTravesty QuantumTravesty 2 minutes ago
Many stocks and Big three indices red while $Hiru green.
HIRU
trader59 trader59 2 minutes ago
Brazen manipulation, computer generated wash trading. The O/S has turned over 100X's today. Don't get trapped with grossly overpriced stock.
SLRX
Twilson Twilson 2 minutes ago
Yes I can open and snip and say's sent to clip board but then nothing on clip board.
Saving Grace Saving Grace 2 minutes ago
Hedge Funds future with GME

https://i.redd.it/twsglmi9she61.jpg

https://preview.redd.it/rip-melvin-capital-v0-r9agzbbdmb091.jpg?auto=webp&s=39365d3182d2fd96c1f647041ff539a21c01ddcb
GME
STRIKERGR21 STRIKERGR21 2 minutes ago
Yes trips will arrive so keep averaging down, INKW is garbage THE paid pumpers and promoters are trying hard to keep this up but they will fail. Only ones making money are the insiders, INKW still has OVER a billion of shares to dump. And nothing any fool can say will alter the eventual out come o
INKW
otc37 otc37 3 minutes ago
looks like all the weak hands are out by now. The only ones dumpingand bashing are probably those fishing for shares are lower levels. At this point they're losing more shares than they are able to scoop up at lower levels. Can't wait from James to drop the hammer with a big 8K
VXIT
Serpico2005 Serpico2005 3 minutes ago
We should be at .03 TODAY with this news today.
SPZI
janice shell janice shell 3 minutes ago
That is true. Biden stepping back and handing the torch to Kamala seems to have got her quite flustered.
dstock07734 dstock07734 3 minutes ago
You cannot even digest the current available science. Where did you collect the audacity to predict the future of science? Don't shame yourself.
NWBO
Lazarus Elite Lazarus Elite 4 minutes ago
Another day with no big news from Tesla. I guess everybody should sell their shares all the way down to 3 cents said the short traders. Giggle giggle.
ELTP
tredenwater2 tredenwater2 4 minutes ago
Im not getting exciting until we close above $10 to break this downward trend. All fake trading as institutional accumulation continues. Reverse psychology trading trying to break or discourage dug in retail longs.

All in my humble opinion of course.
AVXL
newflow newflow 4 minutes ago
No problem.
COOP
MightyX MightyX 4 minutes ago
Let’s see if they close @.0003 unincentivized.
TPTW
stressfreeliving stressfreeliving 4 minutes ago
$HIRU on watch $
HIRU
urge2surge urge2surge 5 minutes ago
The early birds are here for sure. Majority of available shares garnered to. The momo will really start as the frenzy for shares by the general traders try to get in imo. There's a lot of bids waiting for more shares to. Principal MMS garnering control positions on L2. What's not to like eh?
IDVV
d-k d-k 5 minutes ago
Twilson, do you have Windows 11?
WeTheMarket WeTheMarket 5 minutes ago
Recent Linkedin post.
https://www.linkedin.com/posts/chris-castiglione_we-are-solving-the-biggest-problem-in-the-activity-7221580723940392960-SlFI/

https://investorshub.advfn.com/uimage/uploads/2024/7/23/kznsrNKLA_1.png
https://investorshub.advfn.com/uimage/uploads/2024/
FCEL
subslover subslover 5 minutes ago
We all can LOL all we want but when you look at the scope of this being a public Company, what MR Young did is brilliant! I had told this to a newbie and scared him off a couple of months ago but here is HYSR just a tad above 01 and it's assigned "penny stock exempt"! You show me another OTC Company
HYSR
Maxthedog Maxthedog 5 minutes ago
Who would have made a better partner for the Adderall's ?

The point is ELTP has the money to payoff the loan from Hakim. It was a loan cause eltp didn't have the money. But because adderall is doing great, he's holding onto the drug ? Why ?
ELTP
sc00pnDump sc00pnDump 5 minutes ago
This peculiar ticker has done well over the years, as too the other tickers he runs
FONU
newflow newflow 5 minutes ago
"WAND", "PALADIN", "BONANZA" MAY WE ARE MOVING NEAR THE TREASURE SOON!!!!
COOP
LVerstee LVerstee 6 minutes ago
Indeed, your professionalism is seriously lacking. Wholeheartedly agree on that.

And tomorrow the definitive proof of that will show.

After that it will be a different topic.
ITUP
WeTheMarket WeTheMarket 6 minutes ago
IGTM, you conveniently neglected the positive quotes from the article.
Link to article https://www.fool.com/investing/2024/07/23/forget-nvidia-billionaires-sell-buy-hypergrowth-ai/

"The lure of Plug Power as an investment is the high-ceiling potential of renewable energy as it
FCEL
JLuv1982 JLuv1982 6 minutes ago
Crickets… He must be on his quiet period
CUBT
georgejjl georgejjl 6 minutes ago
Part A of the phase 2 Anavex 3-71 schizophrenia trial has been completed. I believe that Part B of the phase 2 Anavex 3-71 schizophrenia trial will be completed before the end of summer 2024.

https://classic.clinicaltrials.gov/ct2/show/NCT06245213

Good luck and GOD bles
AVXL

Your Recent History

EU
GNRO
GeNeuro
BOV
GOLL11
GOL PN
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

United States
Company
Business
Popular
Get The App
App Store
Google Play

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved